Fremont, CA, United States of America

Solomon Ugashe

This inventor holds 1 USPTO granted patent. Top assignee: Chemocentryx, Inc.. Active years: 2009.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2009

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Solomon Ugashe: Innovator in Pharmaceutical Chemistry

Introduction

Solomon Ugashe is a notable inventor based in Fremont, CA, who has made significant contributions to the field of pharmaceutical chemistry. His work primarily focuses on developing compounds that target specific receptors involved in various diseases.

Latest Patents

Ugashe holds a patent for "Aryl sulfonamides," which describes compounds that act as potent antagonists of the CCR9 receptor. These compounds have been validated through animal testing for their effectiveness in treating inflammation, a key characteristic of CCR9-mediated diseases. The aryl sulfonamide derivatives he developed are not only useful in pharmaceutical compositions but also serve as controls in assays for identifying CCR9 antagonists.

Career Highlights

Currently, Solomon Ugashe is employed at Chemocentryx, Inc., where he continues to advance his research in pharmaceutical innovations. His work has the potential to lead to new treatments for diseases associated with the CCR9 receptor, showcasing his commitment to improving healthcare outcomes.

Collaborations

Ugashe collaborates with talented professionals in his field, including Zheng Wei and John Jessen Wright. Their combined expertise enhances the research and development efforts at Chemocentryx, Inc.

Conclusion

In summary, Solomon Ugashe is a dedicated inventor whose work on aryl sulfonamides represents a significant advancement in the treatment of CCR9-mediated diseases. His contributions to pharmaceutical chemistry are noteworthy and have the potential to impact many lives positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…